A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)

European Journal of Cancer

Volumn 48, Issue 5, 2012, Pages 713-720

  Sebban, C ^a   Lefranc, A ^a   Perrier, L ^a,b   Moreau, P ^c   Espinouse, D ^d   Schmidt, A ^e   Kammoun, L ^f   Ghesquieres, H ^a   Ferlay, C ^a   Bay, J O ^g   Lissandre, S ^h   Perol D ^a   Michallet, M ⁱ   Quittet, P ^j  

^a CENTRE LÉON BÉRARD   (France)

^b GATE Lyon Saint Etienne   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f CENTRE HENRI BECQUEREL   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h UNIVERSITY HOSPITAL OF TOURS   (France)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j HÔPITAL SAINT ELOI   (France)

more..

Author keywords

Chemotherapy; Clinical trial; Cost effectiveness analysis; Filgrastim; Lymphoma; Myeloma; Pegfilgrastim; Transplantation

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELOMA; NEUTROPHIL COUNT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84858702393     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.12.016     Document Type: Article

References (35)

1. T. Philip, J.O. Armitage, and G. Spitzer High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma N Engl J Med 316 1987 1493 1498 (Pubitemid 17076232)
2. M. Crump, A.M. Smith, and J. Brandwein High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant J Clin Oncol 11 1993 704 711 (Pubitemid 23105679)
3. J.M. Vose, J.R. Anderson, and A. Kessinger High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma J Clin Oncol 11 1993 1846 1851 (Pubitemid 23304606)
4. M. Attal, J.L. Harousseau, and A.M. Stoppa A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 1996 91 97 (Pubitemid 26240110)
5. T.J. Smith, J. Khatcheressian, and G.H. Lyman 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 2006 3187 3205 (Pubitemid 46638957)
6. M.S. Aapro, J. Bohlius, and D.A. Cameron 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 2011 8 32
7. G. Molineux, O. Kinstler, and B. Briddell A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans Exp Hematol 27 1999 1724 1734
8. G. Molineux Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients Anticancer Drugs 14 2003 259 264 (Pubitemid 36583810)
9. F.A. Holmes, J.A. O'Shaughnessy, and S. Vukelja Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20 2002 727 731 (Pubitemid 34111380)
10. S. George, F. Yunus, and D. Case Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma Leuk Lymphoma 44 2003 1691 1696 (Pubitemid 37221042)
11. J.M. Vose, M. Crump, and H. Lazarus Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma J Clin Oncol 21 2003 514 519 (Pubitemid 46606482)
12. S.W. Lane, J. Crawford, and M. Kenealy Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy Leuk Lymphoma 47 2006 1813 1817 (Pubitemid 44649765)
13. M.H. Jagasia, J.P. Greer, and D.S. Morgan Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study Bone Marrow Transplant 35 2005 1165 1169 (Pubitemid 40895172)
14. P.B. Staber, R. Holub, W. Linkesch, H. Schmidt, and P. Neumeister Fixed-dose single administration of pegfilgrastim vs daily filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation Bone Marrow Transplant 35 2005 889 893 (Pubitemid 40667631)
15. G. Vanstraelen, P. Frere, and M.C. Ngirabacu Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation Exp Hematol 34 2006 382 388
16. R. Fenk, N. Hieronimus, and U. Steidl Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma Exp Hematol 34 2006 1296 1302 (Pubitemid 44374839)
17. A. Ballestrero, D. Boy, and R. Gonella Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas Ann Hematol 87 2008 49 55 (Pubitemid 350182541)
18. M. Martino, G. Pratico, and G. Messina Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients Eur J Haematol 77 2006 410 415 (Pubitemid 44483944)
19. Arrêté du 02 janvier 2008 relatif au tarif de cession des produits sanguins labiles. Journal Officiel de la République Franaise 2008. Available from: http://ile-de-france.sante.gouv.fr/img/pdf/joe-20080210- 0014.pdf.
20. The economic evaluation at the French National Authority: principles and methods. French National Authority for Health 2011. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/ guide-methodo-vf.pdf.
21. S. Mathew, N. Adel, and R.D. Rice Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients Bone Marrow Transplant 45 2010 1522 1527
22. P. Samaras, M. Blickenstorfer, and R.D. Siciliano Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim Ann Hematol 90 2011 89 94
23. P. Samaras, E.M. Buset, and R.D. Siciliano Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation Oncology 79 2010 93 97
24. M. Martino, G. Pratico, and G. Messina Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients Eur J Haematol 77 2006 410 415 (Pubitemid 44483944)
25. R. Rifkin, G. Spitzer, and G. Orloff Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma Clin Lymphoma Myeloma Leuk 10 2010 186 191
26. A. Gerds, M. Fox-Geiman, and K. Dawravoo Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation Biol Blood Marrow Transplant 16 2010 678 685
27. L. Castagna, S. Bramanti, and A. Levis Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support Ann Oncol 21 2010 1482 1485
28. Ziakas PD, Kourbeti IS. Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide? Clin Transplant. doi:10.1111/j.1399-0012.2011.01532.x.
29. C. Faucher, A.G. Le Corroller, and C. Chabannon Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study Bone Marrow Transplant 17 1996 533 536 (Pubitemid 26125701)
30. A.M. de Azevedo, M. Nucci, and A. Maiolino A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation Bone Marrow Transplant 29 2002 745 751 (Pubitemid 34618905)
31. G. Vanstraelen, P. Frere, and M.C. Ngirabacu Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation Exp Hematol 34 2006 382 388
32. L.F. Porrata, D.J. Inwards, and S.M. Ansell Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study Biol Blood Marrow Transplant 14 2008 807 816 (Pubitemid 351773157)
33. G. Lyman, A. Lalla, R. Barron, and R.W. Dubois Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States Curr Med Res Opin 25 2009 401 411
34. A. Eldar-Lissai, L.E. Cosler, E. Culakova, and G.H. Lyman Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy Value Health 11 2008 172 179 (Pubitemid 351473616)
35. F. Ferrara, T. Izzo, and C. Criscuolo Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis Hematol Oncol 29 2011 139 143